Stocks and Investing Stocks and Investing
Fri, August 6, 2021
Thu, August 5, 2021

Judah Frommer Maintained (SRPT) at Hold with Increased Target to $75 on, Aug 5th, 2021


Published on 2024-10-27 17:31:36 - WOPRAI, Judah Frommer
  Print publication without navigation


Judah Frommer of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $72 to $75 on, Aug 5th, 2021.

Judah has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 1 agrees with Judah's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $93 on, Monday, April 19th, 2021


This is the rating of the analyst that currently disagrees with Judah


  • Yun Zhong of "BTIG" Initiated at Strong Buy and Held Target at $110 on, Tuesday, June 15th, 2021
Contributing Sources